Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | POLB | P06746 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.51 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.51 |
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.51 |
| ▸ | GALR2 | O43603 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30542027 | 1.00 | MAPT (0.51) | MAPTKMT2APOLBALDH1A1MEN1 | |
| SCHEMBL25368037 | 0.86 | MAPT (0.51) | MAPTKMT2APOLBALDH1A1MEN1 | |
| SCHEMBL413683 | 0.85 | MAPT (0.50) | MAPTKMT2APOLBALDH1A1MEN1 | |
| SCHEMBL13997802 | 0.82 | PGK1 (0.44) | MAPTKMT2APOLBALDH1A1MEN1 | |
| SCHEMBL19690963 | 0.82 | GLP1R (0.41) | MAPTKMT2APOLBALDH1A1MEN1 | |
| SCHEMBL12544826 | 0.81 | MAPT (0.40) | MAPTKMT2APOLBALDH1A1MEN1 | |
| SCHEMBL27028466 | 0.80 | MAPT (0.46) | MAPTKMT2APOLBALDH1A1MEN1 | |
| SCHEMBL25363603 | 0.80 | ALDH1A1 (0.46) | MAPTKMT2APOLBALDH1A1MEN1 | |
| SCHEMBL1630321 | 0.80 | ALDH1A1 (0.46) | MAPTKMT2APOLBALDH1A1MEN1 | |
| SCHEMBL27028461 | 0.80 | MEN1 (0.46) | MAPTKMT2APOLBALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4720057-A2 | COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF | Oncopia Therapeutics, Inc. D/B/A SK Life Science Labs (US) | 2026-04-08 | — | — | EP | disclosed |
| WO-2025049976-A1 | COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF | ONCOPIA THERAPEUTICS, INC. D/B/A SK LIFE SCIENCE LABS (US) | 2025-03-06 | — | — | WO | disclosed |
| WO-2024249888-A2 | COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF | ONCOPIA THERAPEUTICS, INC. D/B/A SK LIFE SCIENCE LABS (US) | 2024-12-05 | — | — | WO | disclosed |
| US-20240383903-A1 | Modulators of STING (Stimulator of Interferon Genes) | PFIZER INC. (US) | 2024-11-21 | — | — | US | disclosed |
| US-20240317705-A1 | POTASSIUM CHANNEL MODULATORS | NOVARTIS AG (CH) | 2024-09-26 | — | — | US | disclosed |
| US-11964978-B2 | Modulators of STING (stimulator of interferon genes) | PFIZER INC. (US) | 2024-04-23 | — | — | US | disclosed |
| EP-4308563-A1 | MODULATORS OF STING (STIMULATOR OF INTERFERON GENES) | Pfizer Inc. (US) | 2024-01-24 | — | — | EP | disclosed |
| CN-117321055-A | Modulators of STING (interferon gene stimulators) | 辉瑞公司 | 2023-12-29 | — | — | CN | disclosed |
| CN-117186092-A | Ring-fused compound, preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2023-12-08 | — | — | CN | disclosed |
| CN-117088871-A | Ring-fused compound, preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2023-11-21 | — | — | CN | disclosed |
| EP-1888584-B1 | 1, 6 -DIHYDRO- 1,3, 5, 6-TETRAAZA-AS-INDACENE BASED TRICYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME AS INHIBITORS OF IKK ENZYME ACTIVITY | BRISTOL MYERS SQUIBB CO (US) | 2010-04-21 | — | — | EP | disclosed |
| US-20100035934-A1 | PYRIDINYL-PYRAZOLE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S | 2010-02-11 | — | — | US | disclosed |
| EP-2114916-A2 | PYRIDINYL-PYRAZOLE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NeuroSearch A/S (DK) | 2009-11-11 | — | — | EP | disclosed |
| US-7557211-B2 | 8H-imidazo[4,5-D]thiazolo[4,5-B]pyridine based tricyclic compounds and pharmaceutical compositions comprising same | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-07-07 | — | — | US | disclosed |
| US-7557211-B2 | 8H-imidazo[4,5-D]thiazolo[4,5-B]pyridine based tricyclic compounds and pharmaceutical compositions comprising same | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-07-07 | — | — | US | disclosed |
| WO-2008092942-A2 | PYRIDINYL-PYRAZOLE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S (DK) | 2008-08-07 | — | — | WO | disclosed |
| EP-1888584-A1 | 1, 6 -DIHYDRO- 1,3, 5, 6-TETRAAZA-AS-INDACENE BASED TRICYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME AS INHIBITORS OF IKK ENZYME ACTIVITY | Brystol-Myers Squibb Company (US) | 2008-02-20 | — | — | EP | disclosed |
| US-20060270654-A1 | 1,6-Dihydro-1,3,5,6-Tetraaza-as-indacene based tricyclic compounds and pharmaceutical compositions comprising same | BRISTOL-MYERS SQUIBB COMPANY | 2006-11-30 | — | — | US | disclosed |
| WO-2006122137-A1 | 1, 6 -DIHYDRO- 1,3, 5, 6-TETRAAZA-AS-INDACENE BASED TRICYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME AS INHIBITORS OF IKK ENZYME ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-11-16 | — | — | WO | disclosed |
| US-20060128741-A1 | 8H-imidazo[4,5-D]thiazolo[4,5-B]pyridine based tricyclic compounds and pharmaceutical compositions comprising same | BRISTOL-MYERS SQUIBB COMPANY | 2006-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240317705-A1 | POTASSIUM CHANNEL MODULATORS | KCNJ11, KCNJ2, KCNJ1 | MAPT 2009/4885KMT2A 1471/4885POLB 4802/4885 |
| US-20100035934-A1 | PYRIDINYL-PYRAZOLE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | KCNJ2, KCNA3, KCNQ1 | MAPT 1538/4885KMT2A 1455/4885POLB 4745/4885 |
| US-20060270654-A1 | 1,6-Dihydro-1,3,5,6-Tetraaza-as-indacene based tricyclic compounds and pharmaceutical compositions comprising same | IL1R1, IDO1, TLR1 | MAPT 1426/4885KMT2A 3054/4885POLB 4295/4885 |
| US-11964978-B2 | Modulators of STING (stimulator of interferon genes) | STING1, IRF3, CGAS | MAPT 4690/4885KMT2A 4571/4885POLB 185/4885 |
| US-20240383903-A1 | Modulators of STING (Stimulator of Interferon Genes) | STING1, IRF3, CGAS | MAPT 4690/4885KMT2A 4571/4885POLB 185/4885 |
| US-20060128741-A1 | 8H-imidazo[4,5-D]thiazolo[4,5-B]pyridine based tricyclic compounds and pharmaceutical compositions comprising same | IL4, IL5, CYP4B1 | MAPT 2177/4885KMT2A 1969/4885POLB 3193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.